Odyssey Therapeutics, Inc.
ODTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001882782
No open-market purchases or sales by Odyssey Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $652.9M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +59 vs. previous quarter
- 59
- 13F valueReported value at the end of Q2 2026
- $652.9M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding ODTX, Q2 2026
1 superinvestor reports holding Odyssey Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.9%
Odyssey Therapeutics, Inc.'s share of the portfolio
- Shares
- 831,656
- Value
- $15.6M
Latest insider trades
Open-market purchases and sales by Odyssey Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 (view filing)5:10 PM ET | May 11 | 2 days | Coulter James G and 2 othersOther: Former 10% Owner | PPurchase | +1.39M | $18.00 | +$25.0M | +60.4%3.69M after | |
| May 12, 2026 (view filing) | May 8 | 4 days | Dimension Capital II, L.P.Director | PPurchase | +1.11M | $18.00 | +$20.0M | +50.0%3.33M after | |
| May 11, 2026 (view filing)9:11 PM ET | May 11 | Same day | George Simeon and 1 other10% Owner | SSale | −1.78K | $18.00 | −$32.0K | −0.2%814.9K after | 3 lots |
| May 11, 2026 (view filing)9:11 PM ET | May 11 | Same day | George Simeon and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +121.0%1.01M after | 3 lots |
| May 11, 2026 (view filing) | May 8 | 3 days | Leiden Jeffrey MDirector | PPurchase | +5.00K | $20.00 | +$100.0K | +1.9%270.2K after | |
| May 11, 2026 (view filing) | May 8 | 3 days | Haas JasonChief Financial Officer | PPurchase | +1.00K | $20.00 | +$20.0K | +1.6%62.9K after | |
| May 11, 2026 (view filing) | May 11 | Same day | Li Nan (LN)Director | PPurchase | +1.11M | $18.00 | +$20.0M | +50.0%3.33M after | |
| May 11, 2026 (view filing) | May 11 | Same day | Chu ShelleyDirector | PPurchase | +11.1K | $18.00 | +$200.0K | New position11.1K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Odyssey Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5,179,262 | $96.9M | 0.00% | +5,179,262 | New |
| Sr One Capital Management, LP | 3,794,883 | $71.0M | 6.83% | +3,794,883 | New |
| TPG GP A, LLC | 3,690,146 | $69.0M | 1.38% | +3,690,146 | New |
| Lightspeed Management Company, L.L.C. | 3,608,443 | $67.5M | 2.81% | +3,608,443 | New |
| OrbiMed Advisors LLC | 3,001,198 | $56.2M | 1.06% | +3,001,198 | New |
| Sanofi | 1,991,918 | $37.3M | 6.98% | +1,991,918 | New |
| Deerfield Management Company, L.P. (Series C) | 1,046,139 | $19.6M | 0.20% | +1,046,139 | New |
| Sands Capital Ventures, LLC | 875,000 | $16.4M | 2.67% | +875,000 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 831,656 | $15.6M | 1.87% | +831,656 | New |
| General Catalyst Group Management, LLC | 810,272 | $15.2M | 8.04% | +810,272 | New |